Targeting BCMA in multiple myeloma: designs, challenges, and future directions
Abstract Chimeric antigen receptor (CAR) T cell therapy has emerged as a groundbreaking immunotherapy, demonstrating significant efficacy in treating B cell malignancies. In the context of multiple myeloma (MM), B cell maturation antigen (BCMA) has been identified as a critical target, driving the d...
Saved in:
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Springer
2025-02-01
|
| Series: | Cancer Immunology, Immunotherapy |
| Subjects: | |
| Online Access: | https://doi.org/10.1007/s00262-024-03913-0 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832571643215478784 |
|---|---|
| author | Yi Hu Yuetao Xie Xiaodong Wang Lufeng Yang He Geng Zugang Yi Yao Zhang Lin Ma Fang Chen |
| author_facet | Yi Hu Yuetao Xie Xiaodong Wang Lufeng Yang He Geng Zugang Yi Yao Zhang Lin Ma Fang Chen |
| author_sort | Yi Hu |
| collection | DOAJ |
| description | Abstract Chimeric antigen receptor (CAR) T cell therapy has emerged as a groundbreaking immunotherapy, demonstrating significant efficacy in treating B cell malignancies. In the context of multiple myeloma (MM), B cell maturation antigen (BCMA) has been identified as a critical target, driving the development of CAR T cell therapies designed to address this plasma cell cancer. Various CAR designs, utilizing different BCMA recognition domains, have yielded promising clinical results, leading to the approval of two BCMA-targeting CAR T cell therapies by the US Food and Drug Administration (FDA) for the treatment of MM. This review uniquely examines the BCMA CAR T cell landscape, emphasizing the design of recognition domains, clinical efficacy, and patient outcomes. It critically addresses emerging challenges such as antigen escape and toxicity profiles, which have surfaced alongside therapeutic advances. Moreover, the review spotlights cutting-edge developments, including dual-targeting CAR T strategies, advancements in CAR T cell manufacturing, and innovative allogeneic CAR T approaches utilizing healthy donor cells. By detailing both the breakthroughs and ongoing challenges in BCMA CAR T cell therapy, this review offers a comprehensive perspective on the current state and future possibilities of CAR T cell therapy for MM and its expanding role in treating hematologic malignancies and beyond. |
| format | Article |
| id | doaj-art-338c1a8a59b14dfb8eab62fc880e6235 |
| institution | Kabale University |
| issn | 1432-0851 |
| language | English |
| publishDate | 2025-02-01 |
| publisher | Springer |
| record_format | Article |
| series | Cancer Immunology, Immunotherapy |
| spelling | doaj-art-338c1a8a59b14dfb8eab62fc880e62352025-02-02T12:26:27ZengSpringerCancer Immunology, Immunotherapy1432-08512025-02-0174311610.1007/s00262-024-03913-0Targeting BCMA in multiple myeloma: designs, challenges, and future directionsYi Hu0Yuetao Xie1Xiaodong Wang2Lufeng Yang3He Geng4Zugang Yi5Yao Zhang6Lin Ma7Fang Chen8Department of Anesthesiology, Shenzhen Children’s HospitalDepartment of Anesthesiology, Shenzhen Children’s HospitalDepartment of Hematology and Oncology, Shenzhen Children’s HospitalDepartment of Anesthesiology, Shenzhen Children’s HospitalDepartment of Anesthesiology, Shenzhen Children’s HospitalDepartment of Anesthesiology, Shenzhen Children’s HospitalDepartment of Anesthesiology, Shenzhen Children’s HospitalDepartment of Anesthesiology, Shenzhen Children’s HospitalDepartment of Anesthesiology, Shenzhen Children’s HospitalAbstract Chimeric antigen receptor (CAR) T cell therapy has emerged as a groundbreaking immunotherapy, demonstrating significant efficacy in treating B cell malignancies. In the context of multiple myeloma (MM), B cell maturation antigen (BCMA) has been identified as a critical target, driving the development of CAR T cell therapies designed to address this plasma cell cancer. Various CAR designs, utilizing different BCMA recognition domains, have yielded promising clinical results, leading to the approval of two BCMA-targeting CAR T cell therapies by the US Food and Drug Administration (FDA) for the treatment of MM. This review uniquely examines the BCMA CAR T cell landscape, emphasizing the design of recognition domains, clinical efficacy, and patient outcomes. It critically addresses emerging challenges such as antigen escape and toxicity profiles, which have surfaced alongside therapeutic advances. Moreover, the review spotlights cutting-edge developments, including dual-targeting CAR T strategies, advancements in CAR T cell manufacturing, and innovative allogeneic CAR T approaches utilizing healthy donor cells. By detailing both the breakthroughs and ongoing challenges in BCMA CAR T cell therapy, this review offers a comprehensive perspective on the current state and future possibilities of CAR T cell therapy for MM and its expanding role in treating hematologic malignancies and beyond.https://doi.org/10.1007/s00262-024-03913-0B cell maturation antigenMultiple myelomaChimeric antigen receptorT cellsImmunotherapy |
| spellingShingle | Yi Hu Yuetao Xie Xiaodong Wang Lufeng Yang He Geng Zugang Yi Yao Zhang Lin Ma Fang Chen Targeting BCMA in multiple myeloma: designs, challenges, and future directions Cancer Immunology, Immunotherapy B cell maturation antigen Multiple myeloma Chimeric antigen receptor T cells Immunotherapy |
| title | Targeting BCMA in multiple myeloma: designs, challenges, and future directions |
| title_full | Targeting BCMA in multiple myeloma: designs, challenges, and future directions |
| title_fullStr | Targeting BCMA in multiple myeloma: designs, challenges, and future directions |
| title_full_unstemmed | Targeting BCMA in multiple myeloma: designs, challenges, and future directions |
| title_short | Targeting BCMA in multiple myeloma: designs, challenges, and future directions |
| title_sort | targeting bcma in multiple myeloma designs challenges and future directions |
| topic | B cell maturation antigen Multiple myeloma Chimeric antigen receptor T cells Immunotherapy |
| url | https://doi.org/10.1007/s00262-024-03913-0 |
| work_keys_str_mv | AT yihu targetingbcmainmultiplemyelomadesignschallengesandfuturedirections AT yuetaoxie targetingbcmainmultiplemyelomadesignschallengesandfuturedirections AT xiaodongwang targetingbcmainmultiplemyelomadesignschallengesandfuturedirections AT lufengyang targetingbcmainmultiplemyelomadesignschallengesandfuturedirections AT hegeng targetingbcmainmultiplemyelomadesignschallengesandfuturedirections AT zugangyi targetingbcmainmultiplemyelomadesignschallengesandfuturedirections AT yaozhang targetingbcmainmultiplemyelomadesignschallengesandfuturedirections AT linma targetingbcmainmultiplemyelomadesignschallengesandfuturedirections AT fangchen targetingbcmainmultiplemyelomadesignschallengesandfuturedirections |